Michael U. Callaghan

Author

Also Known As

Fook-Choe Cheah, Kanin, M., M CALLAGHAN, M Callaghan, M. Callaghan, M. U. CALLAGHAN, M. U. Callaghan, M.U. Callaghan, Michael Callaghan, Michael U Callaghan

152

Publications

4.8K

Citations

H-Index

Concepts

All Affiliations

Children's Hospital of Michigan Wayne State University University of the Witwatersrand Roche (Switzerland)Central Michigan University

About

Michael U. Callaghan is an author at Children's Hospital of Michigan specializing in medicine, cell biology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	19	1.6K
2	Natural Sciences	4	4	643
3	Health Sciences	3	3	292
4	Public Health	3	3	119
5	Biochemistry	2	2	37

Michael U. Callaghan

Publications

4.3K

Citations

H-Index

Page 1

	Year	Citations
Emicizumab Prophylaxis in Hemophilia A with Inhibitors Johannes Oldenburg, Johnny Mahlangu, Benjamin Kim, New England Journal of Medicine	2017	1K
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors Johnny Mahlangu, Johannes Oldenburg, Ido Paz‐Priel, New England Journal of Medicine	2018	708
UPR Pathways Combine to Prevent Hepatic Steatosis Caused by ER Stress-Mediated Suppression of Transcriptional Master Regulators D. Thomas Rutkowski, Jun Wu, Sung-Hoon Back, Developmental Cell Reductive StressTranscriptional RegulationHepatologyPrevent Hepatic SteatosisNatural Sciences	2008	582
Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia Leila Noetzli, Richard Lo, Alisa B. Lee‐Sherick, Nature Genetics Hematological MalignancyMedicinePathogenesisHematologyPathology	2015	322
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies Michael U. Callaghan, Claude Négrier, Ido Paz‐Priel, Blood ThrombosisAntibioticsPediatric HematologyBleed RateHematology	2020	270
Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A Robert Klamroth, Gregory M. Hayes, T. A. Andreeva, Human Gene Therapy	2022	95
The effect of emicizumab prophylaxis on health‐related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study Johannes Oldenburg, Johnny Mahlangu, Willem Buján, Haemophilia	2018	91
Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study Christophe Schmitt, Joanne I. Adamkewicz, Jin Xu, Thrombosis and Haemostasis	2020	91
Genotype-phenotype correlation in combined deficiency of factor V and factor VIII Bin Zhang, Marta Spreafico, Chunlei Zheng, Blood	2008	81
Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection Caterina P. Minniti, Ahmar U. Zaidi, Mehdi Nouraie, Blood Advances Disease ManagementRenal PathologyClinical PredictorsCovid-19Clinical Epidemiology	2021	78

Page 1